Drugs / AMELUBANT
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 113 trials | ||||||
| Phase 1 | NCT02269189 | Apr → Nov 2002 | cystic fibrosis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02265679 | Oct 2001 → Jul 2002 | cystic fibrosis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02265666 | Oct → Nov 2001 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02265640 | Oct → Dec 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02273440 | May → Jul 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02268149 | Apr → Jul 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02265627 | Mar → Sep 2000 | liver disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02273427 | Feb → Mar 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02247375 | Jan → May 2000 | rheumatoid arthritis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02265653 | Nov → Dec 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02266550 | Oct 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02273414 | Jul → Sep 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02265302 | Jun → Dec 1998 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02251210 | May 2001 → Nov 2002 | rheumatoid arthritis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02249247 | Apr 2001 → Aug 2002 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02249338 | Oct 1999 → Apr 2000 | chronic obstructive pulmonary disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02249312 | Jul 1999 → Apr 2000 | asthma | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMELUBANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742420 ↗ |
| Known as | BIIL 284 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02265302 ↗ |
| Known as | BIIL 284 BS | “Metabolism and Pharmacokinetics of \[14C\]-BIIL 284 BS in Healthy Volunteers” NCT02266550 ↗ |
| Known as | LS-49968 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742420 ↗ |
| Action | Inhibit | “Leukotriene B4 receptor 1 antagonist” CHEMBL1742420 ↗ |
| Modality | Small molecule | — CHEMBL1742420 ↗ |
| Route | Oral | “Two Oral Doses of BIIL 284 BS” NCT02247375 ↗ |
| Target | LTB4R | “Leukotriene B4 receptor 1 antagonist” CHEMBL1742420 ↗ |